Xianwen Hu

484 citations
46 papers · 179 indexed · h-index 8

Xianwen Hu

35 papers receiving 174 citations

Peers

Xianwen Hu
Comparison fields: 5 of 45
  • Hematology 34
  • Radiology, Nuclear Medicine and Imaging 51
  • Cancer Research 31
  • Oncology 53
  • Immunology and Allergy 11
Replace Massimo Federico with:
Massimo Federico Italy
Patrick Costello United States
Anna Shvartsur United States
Mounia S. Braza United States
Ryosuke Tajiri Japan
K. Boye France
Manuela Arcamone Italy
Lothar Kanz Germany
Birthe Heitkötter Germany
Gaetana Capobianco Italy
Xianwen Hu relative to Massimo Federico Italy Massimo Federico's profile →
Citations per field
00.5×8.7×
Massimo Federico · 1×
Citations per year

Countries citing papers authored by Xianwen Hu

Since Specialization
Citations

This map shows the geographic impact of Xianwen Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xianwen Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xianwen Hu more than expected).

Fields of papers citing papers by Xianwen Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xianwen Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xianwen Hu. The network helps show where Xianwen Hu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Xianwen Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xianwen Hu Line = papers co-authored together Xianwen Hu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20241
2 20241
3 20240
4 20241
5 20240
6 20240
7 20241
8 20234
9 20235
10 20230
11 20230
12 20231
13 202210
14 20223
15 20224
16 20227
17 20221
18 20223
19 20223
20 20226

About Xianwen Hu

Xianwen Hu is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging, Oncology, Reproductive Medicine and Hematology, having authored 46 papers that have together received 179 indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (9 papers), Radiopharmaceutical Chemistry and Applications (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Multiple Myeloma Research and Treatments (4 papers), Soft tissue tumor case studies (4 papers), Cardiac tumors and thrombi (4 papers), Ovarian cancer diagnosis and treatment (4 papers) and Urologic and reproductive health conditions (4 papers). The work is most often cited by research in Hematology (34 citations), Radiology, Nuclear Medicine and Imaging (51 citations), Cancer Research (31 citations), Oncology (53 citations) and Immunology and Allergy (11 citations). Xianwen Hu has collaborated with scholars based in China and United States. Frequent co-authors include Jiong Cai, Pan Wang, Dandan Li, Haifeng Duan, Chu-Tse Wu, Guohu Di, Pan Wang, Changgeng Ruan, Xiaoping Du and Zhigang Liang. Their work appears in journals such as Frontiers in Medicine, Frontiers in Oncology, Medicine, Scientific Reports and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026